Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 5/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393346 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL5819946 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL5823952 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL13753646 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL13746293 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL196983 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL305904 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL1607862 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL4254400 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 | |
| SCHEMBL4947418 | 0.84 | SLC7A5 (0.56) | OR51E2SLC7A5PTGS1SLC7A11SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834033-B2 | Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine | CELGENE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1733726-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-7005438-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-6762195-B2 | TREATING DISEASES MEDIATED BY TUMOR NECROSIS FACTOR; INHIBIT ANGIOGENESIS AND TREATMENT OF CANCER, INFLAMMATORY, AND AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | disclosed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | OR51E2 947/4885SLC7A5 4481/4885SMN1; SMN2 1759/4885 |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | OR51E2 1271/4885SLC7A5 4376/4885SMN1; SMN2 1474/4885 |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | OR51E2 947/4885SLC7A5 4481/4885SMN1; SMN2 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.